CTLA4 and glioblastoma: Hu et al. (100) demonstrated that meningeal lymphatic vessels play an important role in anti-PD-1/CTLA-4 combination therapy for GBM by establishing a mouse model of GBM, and ablation of the dorsal meningeal lymphatic vessels in the tested mice significantly reduced the effect of anti-PD-1/CTLA-4 combination therapy.